

April 7, 2005

**Contact Information:**  
Maryann Roefaro, CEO  
5008 Brittonfield Pkwy,  
PO Box 2010  
E. Syracuse, NY 13057-4510  
(315) 472-1051

**\*\*\* For Immediate Release \*\*\***

**Hematology-Oncology Associates of CNY Affiliates with Fox Chase Cancer  
Center for Clinical Cancer Research Trials**

Hematology-Oncology Associates of CNY whose main office is located at 5008 Brittonfield Parkway is pleased to announce their acceptance as an affiliate of the Fox Chase Cancer Center Research Base. Through the National Cancer Institute's (NCI), Community Clinical Oncology Program (CCOP), Fox Chase becomes Hematology-Oncology Associates' sixth research base affiliation.

The Fox Chase Cancer located in Philadelphia is an NCI-designated Research Base with the goal of reducing the incidence of cancer and its associated morbidity and mortality. This is achieved through the identification, testing and evaluation of interventions in controlled clinical trials. The clinical trials from the Fox Chase Cancer Center integrate the disciplines of chemoprevention and behavioral research, cancer screening, symptom management, quality of life issues and other studies related to cancer outcome and patient care.

"It is a tremendous privilege to be the only cancer practice in Central New York that can offer clinical cancer trials from the Fox Chase Cancer Center", stated Maryann Roefaro, COO of Hematology Oncology Associates. "To allow our patients to participate in clinical trials offered at that premier cancer center is a blessing to our community"

The University of Rochester Cancer Center and the MD Anderson Cancer Center in Texas are among Hematology-Oncology's other prestigious research base affiliations. In addition, the other three research base affiliates provide access to clinical cancer research trials from the Mayo Clinic, Memorial Sloan Kettering, Roswell Park and Brigham and Women's Hospital. Hematology-Oncology Associates is one of only two Community Clinical Oncology Programs (CCOPs) in New York State – the other being on Long Island. This affiliation is allowed and monitored by the National Cancer Institute. "Patients can remain with our practice to participate in these associated protocols and research trials. We are able to offer investigational drug therapies and cutting edge treatments to our patients – and they don't need to travel to Philadelphia, Rochester, or Texas" said Roefaro.

###